Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

President-elect Donald Trump and his incoming administration are unlikely to attempt a wholesale restructuring of U.S.

"Pair this off with the continued surge of inflows to equity ETFs and it creates a developing case of hot sentiment. Keep in ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

By Gnaneshwar Rajan and Maggie Fick (Reuters) -U.S.-based vaccine maker Novavax said on Wednesday it will sell its ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...

JetBlue Airways raised its revenue guidance for the year after bookings in November and December were higher than anticipated immediately following the U.S. presidential election. The world's ...

The Alliance for Pharmacy Compounding rebutted Novo's FDA petition to bar compounding pharmacies from copying its weight loss ...